{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T03:42:52Z","timestamp":1773632572798,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.pep.2013.03.008","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T04:05:42Z","timestamp":1364529942000},"page":"124-130","source":"Crossref","is-referenced-by-count":3,"title":["High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV"],"prefix":"10.1016","volume":"89","author":[{"given":"Kongtian","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weina","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2013.03.008_b0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2249.2011.04409.x","article-title":"In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells","volume":"166","author":"Rossi","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.pep.2013.03.008_b0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cellsig.2004.04.007","article-title":"Chemokine receptor CCR5: insights into structure, function, and regulation","volume":"16","author":"Oppermann","year":"2004","journal-title":"Cell. Signal."},{"key":"10.1016\/j.pep.2013.03.008_b0015","doi-asserted-by":"crossref","first-page":"10620","DOI":"10.1074\/jbc.M010867200","article-title":"The BBXB motif of RANTES is the principal site for heparin binding and controls receptor selectivity","volume":"276","author":"Proudfoot","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pep.2013.03.008_b0020","doi-asserted-by":"crossref","first-page":"17161","DOI":"10.1074\/jbc.271.29.17161","article-title":"Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha","volume":"271","author":"Raport","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pep.2013.03.008_b0025","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/1521-4141(200107)31:7<2170::AID-IMMU2170>3.0.CO;2-D","article-title":"Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils","volume":"31","author":"Struyf","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.pep.2013.03.008_b0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/381667a0","article-title":"HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5","volume":"381","author":"Dragic","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.pep.2013.03.008_b0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/COH.0b013e328356e9f3","article-title":"Use of (alternative) coreceptors for HIV entry","volume":"7","author":"Pollakis","year":"2012","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.pep.2013.03.008_b0040","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1128\/JVI.78.8.4037-4047.2004","article-title":"Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian\/human immunodeficiency virus","volume":"78","author":"Chackerian","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.pep.2013.03.008_b0045","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/431519","article-title":"Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals","volume":"192","author":"Brumme","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pep.2013.03.008_b0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/428096","article-title":"Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection","volume":"191","author":"Moyle","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pep.2013.03.008_b0055","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"Dean","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.pep.2013.03.008_b0060","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.pep.2013.03.008_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2009.07.022","article-title":"Entry inhibitors in the treatment of HIV-1 infection","volume":"85","author":"Tilton","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.pep.2013.03.008_b0070","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1073\/pnas.042708299","article-title":"HIV\u2019s response to a CCR5 inhibitor: I\u2019d rather tighten than switch!","volume":"99","author":"Farber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pep.2013.03.008_b0075","first-page":"208","article-title":"Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists","volume":"14","author":"Poveda","year":"2012","journal-title":"AIDS Rev."},{"key":"10.1016\/j.pep.2013.03.008_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/TCRM.S1997","article-title":"New approaches in the treatment of HIV\/AIDS \u2013 focus on maraviroc and other CCR5 antagonists","volume":"4","author":"Schlecht","year":"2008","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.pep.2013.03.008_b0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pep.2006.02.020","article-title":"Construction, purification, and immunogenicity of recombinant cystein\u2013cystein type chemokine receptor 5 vaccine","volume":"49","author":"Wu","year":"2006","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2013.03.008_b0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.pep.2005.03.032","article-title":"Production and purification of recombinant human BLyS mutant from inclusion bodies","volume":"42","author":"Xue","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2013.03.008_b0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0092-8674(03)00508-7","article-title":"Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120","volume":"114","author":"Choe","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pep.2013.03.008_b0100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/314987","article-title":"Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression","volume":"180","author":"de Roda Husman","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pep.2013.03.008_b0105","first-page":"179","article-title":"CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4years on","volume":"20","author":"Westby","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pep.2013.03.008_b0110","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14656566.8.7.923","article-title":"Access denied? The status of co-receptor inhibition to counter HIV entry","volume":"8","author":"Biswas","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.pep.2013.03.008_b0115","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pep.2013.03.008_b0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pep.2013.03.008_b0125","doi-asserted-by":"crossref","unstructured":"L. Li, T. Sun, K. Yang, P. Zhang, W.Q. Jia, Monoclonal CCR5 antibody for treatment of people with HIV infection, Cochrane Database Syst. Rev. (2010) CD008439.","DOI":"10.1002\/14651858.CD008439.pub2"},{"key":"10.1016\/j.pep.2013.03.008_b0130","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jinf.2012.05.008","article-title":"Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials","volume":"65","author":"Caseiro","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.pep.2013.03.008_b0135","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jcv.2012.06.021","article-title":"Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc","volume":"55","author":"McNicholas","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.pep.2013.03.008_b0140","doi-asserted-by":"crossref","first-page":"e38755","DOI":"10.1371\/journal.pone.0038755","article-title":"Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc","volume":"7","author":"Savkovic","year":"2012","journal-title":"PloS One"}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592813000533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592813000533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T14:23:42Z","timestamp":1562855022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592813000533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1046592813000533"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2013.03.008","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}